
Pengyue Zhang, PhD
Associate Professor of Biostatistics & Health Data Science
Bio
I am an Associate Professor in the Department of Biostatistics and Health Data Science. My research interests include the development and application of statistical methods for mining real-world health data. I have served as Multiple Principal Investigators on four NIH R01 grants. Additionally, I have 36 research publications in methodological journals, such as Statistics in Medicine and Journal of Biomedical Informatics, as well as clinical journals, including Alzheimer’s & Dementia and the Clinical Journal of the American Society of Nephrology.
Key Publications
Y Shi, A Sun, J Xu, Y Yang, A Saykin, F Cheng, and P Zhang. Real-world relationship between blood biomarker-based PhenoAge, metformin, and Alzheimer’s disease. Alzheimer's & Dementia: TRCI, 2026
Y Shi, A Sun, Y Yang, H Nan, J Xu, M Shan, MT Eadon, J Su, and P Zhang. A Dose-Aware Model for Revealing Dose-Risk Relationship of Drug-Drug Interaction. CPT: Pharmacometrics & Systems Pharmacology, 2025
J Xu, A Sun, Y Yang, Y Shi, D Lai, J Su, L Li, D Zeng, A Saykin, F Cheng, Y Liu, P Zhang. Real-World Observations on Neuroinflammation-Related Drug Responses in Alzheimer's Disease. Journal of Alzheimer’s Disease, 2025
P Zhang, C Mao, A Sun, Y Yang, Y Hou, Z Fu, T Babak, JB Leverenz, AA Pieper, Y Luo, J Cummings, F Cheng. Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease. Alzheimer’s and Dementia, 2025
Y Shi, A Sun, H Nan, Y Yang, J Xu, MT Eadon, J Su, P Zhang. A trajectory-informed model for detecting drug-drug-host interaction from real-world data. Journal of Biomedical Informatics, 2025
J Xu, A Sun, Y Yang, Y Shi, J Su, MT Eadon and P Zhang. Risk of urinary tract infections with SGLT-2 inhibitors in subpopulations with abnormal genitourinary pathology. Clinical Journal of the American Society of Nephrology, 2025
Y Shi, Y Yang, R Liu, A Sun, X Peng, Lang Li, P Zhang and P Zhang. A drug similarity-based early adverse drug event detection approach. Drug Safety, 2025
Y Shi, MT Eadon, Y Chen, A Sun, Y Yang, C Chiang, MM Donneyong, J Su and P Zhang. A precision mixture risk model to identify adverse drug events in subpopulations using a case-crossover design. Statistics in Medicine, 2024
P Zhang, Y Hou, W Tu, N Campbell, AA Pieper, JB Leverenz, S Gao, J Cummings and F Cheng. Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2023
| Year | Degree | Institution |
|---|---|---|
| 2016 | PhD | Indiana University |
| 2011 | MS | Purdue University |
| 2008 | BS | Tianjin Normal University |